ERBB2 and hematologic disorder: CAR-T cells have also been tested in various solid tumors (i.e., against human epidermal growth factor receptor 2 (HER2) or mesothelin) [23,24], however, the results have been far less promising compared to hematologic malignancies, indicating that solid tumors can escape and/or suppress CAR-T cells.